AR plays a pivotal role in the development and progression of localized and metastatic prostate cancer.[1] Despite advancements in medical treatment, prostate cancer remains the second leading cause of cancer‐related deaths among men in the United States and the fifth leading cause of cancer‐related deaths worldwide.[2, 3] In addition to surgery and radiotherapy, androgen deprivation therapy (ADT) is the first‐line treatment for patients with prostate cancer, to reduce hormone levels in the tumors. This evidence concerns the gene AR and cancer.